AI Article Synopsis
- Adult bone marrow-derived mesenchymal stem cells (MSCs) have various beneficial properties that help improve recovery in conditions like cerebral ischemia and spinal cord injuries.
- Research shows that these cells can aid recovery through mechanisms such as replacing damaged cells and promoting new blood vessel growth.
- Initial human studies involving the intravenous delivery of MSCs in stroke patients have been conducted, and this review discusses their repair capabilities, the current state of clinical trials, and future possibilities for MSC therapy.
Article Abstract
Adult bone marrow-derived mesenchymal stem cells (MSCs) display a spectrum of functional properties. Transplantation of these cells improves clinical outcome in models of cerebral ischemia and spinal cord injury via mechanisms that may include replacement of damaged cells, neuroprotective effects, induction of axonal sprouting, and neovascularization. Therapeutic effects have been reported in animal models of stroke after intravenous delivery of MSCs, including those derived from adult human bone marrow. Initial clinical studies on intravenously delivered MSCs have now been completed in human subjects with stroke. Here, we review the reparative and protective properties of transplanted MSCs in stroke models, describe initial human studies on intravenous MSC delivery in stroke, and provide a perspective on prospects for future progress with MSCs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.molmed.2012.02.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!